Horiba ABX SAS

Horiba ABX SAS is the French medical-diagnostics business historically known as ABX Company or ABX SA and now associated with the HORIBA Medical segment of Horiba, Ltd. The business is headquartered in Montpellier and focuses on in vitro diagnostic systems used for laboratory analysis. Its portfolio covers hematology, clinical chemistry, and hemostasis, combining automated analyzers with the reagents and supporting systems required for routine biological testing. The company was founded in 1983 as ABX Company. Its early development was closely associated with hematology instrumentation, including the Minos analyzer, which was described at the time of its introduction as the smallest hematology analyzer in the world. The business was acquired by Horiba in 1996, becoming part of a broader Japanese measurement and analytical-instrument group. Following the acquisition, the former ABX business continued to operate as a specialist medical-diagnostics organization while benefiting from Horiba's international infrastructure, engineering capabilities, and presence in other measurement markets. HORIBA Medical serves a wide range of laboratory customers, including public and private medical laboratories, hospitals, clinics, university hospitals, physicians, and other healthcare institutions. Its systems are intended to support biological analysis across different laboratory environments, from routine testing to more demanding high-throughput workflows. The segment manages the development and manufacture of diagnostic instruments and reagents and supports their distribution and use internationally. The medical business is one of five principal activity areas within the Horiba group, alongside automotive test systems, environmental measurement, semiconductor measurement, and scientific instruments. Reference material describes HORIBA Medical as having a presence in more than 110 countries. It also reports production of approximately 7,500 instruments and 10,000 tonnes of reagents annually, together with a workforce of approximately 1,080 employees; these figures are associated with the cited 2014-era description and should not be treated as current measurements. The brand's positioning is built around laboratory automation, analytical reliability, integrated instrument-and-reagent offerings, and international service support. Unlike a consumer-facing healthcare brand, Horiba ABX primarily operates in the professional diagnostics market, where purchasing decisions are influenced by analytical performance, workflow efficiency, regulatory requirements, installed-base compatibility, service, and total operating cost. Its identity therefore combines the specialist heritage of ABX in blood-cell analysis with Horiba's wider reputation in precision measurement and instrumentation.

Horiba ABX SAS traces its origins to ABX Company, a French medical-instrument business established in 1983. The company developed a specialist position in in vitro diagnostics, particularly hematology, a field concerned with the analysis of blood cells and related biological parameters. Its early product history included the Minos hematology analyzer, which was presented as an unusually compact system for its time and helped establish ABX's identity as an innovator in laboratory instrumentation. In 1996, Horiba acquired ABX SA. The transaction brought the French diagnostics specialist into Horiba's expanding international measurement group. Horiba had been active in measurement technology since 1945, had incorporated its present company structure in 1953, and had developed businesses spanning automotive, environmental, medical, semiconductor, and scientific applications. The ABX acquisition gave Horiba a dedicated platform in medical diagnostics while adding a French engineering and manufacturing base to its international network. After the acquisition, the business became known as Horiba ABX SAS and formed the core of what is generally described as HORIBA Medical. The subsidiary retained its focus on instruments and consumables for in vitro diagnostic laboratories, while its connection to Horiba enabled broader international distribution and group-level support. HORIBA Medical subsequently expanded its scope beyond hematology to include clinical chemistry and hemostasis. These areas allowed the segment to address a wider range of routine laboratory testing requirements and to offer products to public-sector and private-sector healthcare organizations. The medical segment's business model covers the lifecycle of diagnostic systems, including the design and manufacture of analyzers, the production of reagents, and international commercialization and support. Its instruments are used by biological laboratories, hospitals, clinics, university hospitals, physicians, and other professional users. The reference material describes the segment as serving more than 110 countries and reports approximately 1,080 employees, 7,500 instruments produced, and 10,000 tonnes of reagents produced annually. Those figures are historical, associated with a 2014-era account, and do not establish the subsidiary's current scale. Horiba's broader overseas expansion also shaped the context in which HORIBA Medical developed. The group established American and European subsidiaries in the 1970s and later acquired other specialist businesses, including Instruments SA in 1997. These moves helped diversify Horiba away from dependence on the Japanese industrial market and created a multinational operating structure. Within that structure, Horiba ABX remained identifiable as the French medical-diagnostics operation, while the wider brand architecture increasingly used HORIBA Medical for the segment's international activities. Today, the subject is best understood as a professional diagnostics subsidiary and brand rather than as an independent consumer healthcare company. Its principal market is laboratory medicine, where analyzer performance, reagent compatibility, automation, reliability, service, and regulatory compliance are central to adoption. The company’s historical distinction comes from combining ABX's hematology expertise with Horiba's wider capabilities in precision analysis and global industrial operations.

• 2014

  HORIBA Medical described as an international diagnostics segment

  [1]Horibaen.wikipedia.org

  Contemporary reference material described HORIBA Medical as active in hematology, clinical chemistry, and hemostasis in more than 110 countries, with approximately 1,080 employees.

• 1997

  Expansion of Horiba's European specialist portfolio

  [1]Horibaen.wikipedia.org

  Horiba acquired Instruments SA, another French specialist business, as part of the group's wider European expansion; the transaction was separate from the ABX acquisition but strengthened the surrounding group structure.

• 1996

  Acquisition by Horiba

  [1]Horibaen.wikipedia.org

  Horiba acquired ABX SA, bringing the French blood-cell-counter specialist into the Horiba Group.

• 1983

  ABX Company founded

  [1]Horibaen.wikipedia.org

  ABX Company was established in France as a specialist medical-diagnostics and laboratory-instrumentation business.

• Launch of the Minos hematology analyzer

  [1]Horibaen.wikipedia.org

  ABX introduced the Minos, described in reference material as the smallest hematology analyzer in the world at the time of its launch.

A professional in vitro diagnostics brand serving clinical laboratories with automated analyzers, reagents, and laboratory workflow solutions, with particular heritage in hematology.

• Hematology analyzer

  Minos

  Minos was an early ABX hematology analyzer and a notable product in the company's history. Reference material credits it with being the smallest hematology analyzer in the world at the time of its introduction. The product exemplified ABX's focus on compact automated blood-cell analysis for professional laboratory use.

• Hematology analyzers

  HORIBA Medical hematology systems

  The hematology portfolio is the business's historical core and covers automated instruments used to analyze blood samples in clinical laboratories. Specific current model names and product-generation details are not established by the supplied references, so this entry describes the product family rather than attributing unverified models.

• Clinical chemistry analyzers

  HORIBA Medical clinical chemistry systems

  Clinical chemistry systems form one of the diagnostic areas attributed to HORIBA Medical. They are intended for laboratory measurement of chemical and biochemical parameters in biological samples. The supplied sources do not provide enough detail to identify particular current platforms or launch dates.

• Hemostasis analyzers

  HORIBA Medical hemostasis systems

  Hemostasis systems address laboratory testing related to blood coagulation and related processes. The category expands the former ABX business beyond its original blood-cell-analysis specialization. Specific systems, models, and release dates are not identified in the supplied material.

• In vitro diagnostic reagents

  HORIBA Medical reagents

  Reagents are a central part of the HORIBA Medical offering and are used with the company's diagnostic analyzers. The segment's integrated instrument-and-reagent model supports recurring laboratory testing and helps maintain compatibility across installed systems. The supplied references do not specify individual reagent families or formulations.

• 1996

  Horiba acquires ABX SAM&A

  Background

  ABX had developed specialist expertise in blood-cell counters and in vitro diagnostic equipment. Horiba was diversifying its measurement business across medical and other analytical fields.

  Action taken

  Horiba acquired ABX SA and incorporated the French diagnostics business into its international group, later operating it as Horiba ABX SAS within HORIBA Medical.

  Aftermath

  The acquisition established Horiba's dedicated medical-diagnostics platform and supported the subsequent development of a broader portfolio covering hematology, clinical chemistry, and hemostasis.

  Source

1. 1Horibaen.wikipedia.org